Hardback / bound
|
English
€171.50
- From €15,- no shipping costs.
- 30 days to change your mind and return physical products
Description
There is a growing interest in unmet needs for the development of a new discipline in drug discovery and in university education on polypharmacology.
Zhiguo Wang PhD received his PhD in cardiovascular pharmacology from McGill University, Canada. He is presently the Director of the Division of Drug Discovery, Meditech Institute of Research and Advance (USA) and a Distinguished Professor in the Department of Pharmacology, Harbin Medical University. He is an author of over 150 research articles in prestigious scientific journals and of 6 monographs and 15 book chapters with renowned scientific publishers. His research interests cover cardiovascular disease and pharmacology, molecular pharmacology, epigenetic polypharmacology. His research group is one of the earliest investigators who proposed “one drug, multiple targets” polypharmacology concept and provided the experimental evidence in support of the epigenetic polypharmacology.
Zhiguo Wang PhD received his PhD in cardiovascular pharmacology from McGill University, Canada. He is presently the Director of the Division of Drug Discovery, Meditech Institute of Research and Advance (USA) and a Distinguished Professor in the Department of Pharmacology, Harbin Medical University. He is an author of over 150 research articles in prestigious scientific journals and of 6 monographs and 15 book chapters with renowned scientific publishers. His research interests cover cardiovascular disease and pharmacology, molecular pharmacology, epigenetic polypharmacology. His research group is one of the earliest investigators who proposed “one drug, multiple targets” polypharmacology concept and provided the experimental evidence in support of the epigenetic polypharmacology.